by The global Acute Bacterial Skin And Skin structure Infections Market is estimated to be valued at US$ 3674.6 Mn in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Acute bacterial skin and skin structure infections (ABSSSIs) are often characterized by redness, swelling, pain and warmth of the skin and surrounding soft tissue structures including fascia and muscles. Some examples of ABSSSI include cellulitis, cuts or boils. Due to the increasing prevalence of antibiotic resistance bacterial strains, demand for novel therapeutics for ABSSSIs is growing.
Market key trends:
One of the key trends driving growth in the ABSSSI market is rising adoption of telemedicine. Several companies are focusing on development of telemedicine platforms to diagnosis and manage ABSSSI virtually. For instance, Heal introduced a telemedicine platform that connects patients to board-certified physicians for diagnosis, treatment and ongoing management of conditions like ABSSSI without visiting a clinic. Such telemedicine platforms are expected to drive significant growth as they provide access to care for ABSSSI from the comfort of homes especially in rural areas with limited access to healthcare facilities.
Segment Analysis:
The global acute bacterial skin and skin structure infections market is segmented based on treatment, route of administration, distribution channel, and end user. By treatment, the antibiotics segment currently dominates the market due to high incidence rates of skin infections coupled with high reliance on antibiotic drugs for treatment. Specific drugs that hold high market share include ceftaroline fosamil, tigecycline, and dalbavancin.
Key Takeaways:
The global Acute Bacterial Skin And Skin Structure Infections Market is expected to witness high growth, exhibiting CAGR of 6.0% over the forecast period, due to increasing incidence rates of skin infections driven by rising antibacterial resistance.
Regional analysis:
North America currently dominates the market and is expected to continue its dominance over the forecast period due to high awareness about skin infections and established healthcare system in the region. Asia Pacific is expected to be the fastest growing market owing to rising healthcare spending and increasing incidence of nosocomial infections in densely populated countries of the region.
Key players analysis:
Key players operating in the acute bacterial skin and skin structure infections market are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
